ArticleCancer cell2016
Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 3 pooled it
8.0field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 3 syntheses or guidelines pooled it, 188 citations in OpenAlex.
- Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis.Annals of surgical oncology · 2018Pooled it
- Differential networking meta-analysis of gastric cancer across Asian and American racial groups.BMC systems biology · 2018Pooled it
- Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis.Scientific reports · 2017Pooled it
- Advanced extrahepatic cholangiocarcinoma and gallbladder cancer: Post-hoc analysis of the ABC-01, -02 and -03 clinical trials.JHEP reports : innovation in hepatology · 2026Trial
- Recurrence Patterns of Resected Ampullary Adenocarcinoma and Implications for Multimodal Therapy: A Hidden Genome-Derived Analysis from the Ampullary Cancer Collaborative.Annals of surgical oncology · 2026Article
- Malignant epithelial states drive immune dysfunction in ampulla of Vater carcinoma.Biomarker research · 2026Article
- Deciphering the single-cell molecular landscape of ampullary cancer: A rare gastrointestinal malignancy.iScience · 2026Article
- Recurrent COPA mutation drives R-spondin-independent Wnt activation in intestinal tumors.Nature genetics · 2026Article
- Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas.International journal of molecular sciences · 2026Review
- Article
- Generation of a Biliary Tract Cancer Cell Line Atlas Identifies Molecular Subtypes and Therapeutic Targets.Cancer discovery · 2025Article
- Histologic- and Genomic-Directed Adjuvant Therapy for Ampullary Adenocarcinoma: A Hidden Genome-Derived Analysis.Journal of the National Comprehensive Cancer Network : JNCCN · 2025Article
- Article
- Article
- Integrated proteogenomic characterization of ampullary adenocarcinoma.Cell discovery · 2025Article
- Immunosuppression and phenotypic plasticity in an atlas of human hepatocholangiocarcinoma.Hepatobiliary surgery and nutrition · 2024Article
- Outcomes of Palliative Chemotherapy for Ampulla of Vater Adenocarcinoma: A Multicenter Cohort Study.Gut and liver · 2024Article
- Multiomics integration-based immunological characterizations of adamantinomatous craniopharyngioma in relation to keratinization.Cell death & disease · 2024Article
- Switch of ELF3 and ATF4 transcriptional axis programs the amino acid insufficiency-linked epithelial-to-mesenchymal transition.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.Clinical and translational medicine · 2024Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
40 authors at 13 institutions in 2 countries.
Shinichi YachidaDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo 1040045, Japan; Division of Cancer Genomics, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 1040045, Japan. Electronic address: syachida@ncc.go.jp.
Laura D WoodDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Masami SuzukiDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Erina TakaiDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Yasushi TotokiDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Mamoru KatoDepartment of Bioinformatics, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Claudio LuchiniDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Yasuhito AraiDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Hiromi NakamuraDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Natsuko HamaDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Asmaa ElzawahryDepartment of Bioinformatics, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Fumie HosodaDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Tomoki ShirotaDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Nobuhiko MorimotoDivision of Medical Elemental Technology Development, Department of Advanced Analysis Technology, R&D Group, Olympus Corporation, Tokyo 1630914, Japan.
Kunio HoriDivision of Medical Elemental Technology Development, Department of Advanced Analysis Technology, R&D Group, Olympus Corporation, Tokyo 1630914, Japan.
Jun FunazakiDivision of Medical Elemental Technology Development, Department of Advanced Analysis Technology, R&D Group, Olympus Corporation, Tokyo 1630914, Japan.
Hikaru TanakaDivision of Virology, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Chigusa MorizaneDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo 1040045, Japan.
Takuji OkusakaDepartment of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo 1040045, Japan.
Satoshi NaraHepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, Tokyo 1040045, Japan.
Kazuaki ShimadaHepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, Tokyo 1040045, Japan.
Nobuyoshi HiraokaDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo 1040045, Japan.
Hirokazu TaniguchiDepartment of Pathology and Clinical Laboratories, National Cancer Center Hospital, Tokyo 1040045, Japan.
Ryota HiguchiDepartment of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo 1628666, Japan.
Minoru OshimaDepartment of Gastroenterological Surgery, Kagawa University, Kagawa 7610793, Japan.
Keiichi OkanoDepartment of Gastroenterological Surgery, Kagawa University, Kagawa 7610793, Japan.
Seiko HironoSecond Department of Surgery, Wakayama Medical University, Wakayama 6418509, Japan.
Masamichi MizumaDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai Miyagi 9808575, Japan.
Koji ArihiroDepartment of Anatomical Pathology, Hiroshima University Hospital, Hiroshima 7348551, Japan.
Masakazu YamamotoDepartment of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo 1628666, Japan.
Michiaki UnnoDepartment of Surgery, Tohoku University Graduate School of Medicine, Sendai Miyagi 9808575, Japan.
Hiroki YamaueSecond Department of Surgery, Wakayama Medical University, Wakayama 6418509, Japan.
Matthew J WeissDepartment of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Christopher L WolfgangDepartment of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Toru FurukawaInstitute for Integrated Medical Science, Tokyo Women's Medical University, Tokyo 1628666, Japan.
Hitoshi NakagamaDivision of Carcinogenesis and Cancer Prevention, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Bert VogelsteinDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; The Ludwig Center and The Howard Hughes Medical Institute at Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21287, USA.
Tohru KiyonoDivision of Carcinogenesis and Cancer Prevention, National Cancer Center Research Institute, Tokyo 1040045, Japan.
Ralph H HrubanDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA; Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Tatsuhiro ShibataDivision of Cancer Genomics, National Cancer Center Research Institute, Tokyo 1040045, Japan; Laboratory of Molecular Medicine, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo 1088639, Japan.
National Cancer Centre Japan · JPJohns Hopkins Medicine · USOlympus (Japan) · JPTokyo Women's Medical University · JPGenesis Research Institute · JPKagawa University · JPTohoku University · JPTokyo National Hospital · JPWakayama Medical University · JPCancer Research Center · USHiroshima University Hospital · JPJohns Hopkins University · USSidney Kimmel Cancer Center · US
Funding
Tumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI VOGELSTEIN, BERT · 1993 to 2022
$54.6MCharacterization of the Molecular Determinants of High-Grade Dysplasia in Pancreatic Cancer Precursor LesionsK08DK107781 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI WOOD, LAURA DELONG · 2016 to 2020
$846kHoward Hughes Medical InstituteNCI NIH HHS CA62924NCI NIH HHS P50 CA062924NIDDK NIH HHS K08 DK107781
Abstract
Ampullary carcinomas are highly malignant neoplasms that can have either intestinal or pancreatobiliary differentiation. To characterize somatic alterations in ampullary carcinomas, we performed whole-exome sequencing and DNA copy-number analysis on 60 ampullary carcinomas resected from clinically well-characterized Japanese and American patients. We next selected 92 genes and performed targeted sequencing to validate significantly mutated genes in an additional 112 cancers. The prevalence of driver gene mutations in carcinomas with the intestinal phenotype is different from those with the pancreatobiliary phenotype. We identified a characteristic significantly mutated driver gene (ELF3) as well as previously known driver genes (TP53, KRAS, APC, and others). Functional studies demonstrated that ELF3 silencing in normal human epithelial cells enhances their motility and invasion.
Indexed as
AdultAgedAged, 80 and overDNA-Binding ProteinsExomeFemaleHumansMaleMiddle AgedPancreatic NeoplasmsProto-Oncogene Proteins c-etsTranscription FactorsYoung AdultDNA-Binding ProteinsELF3 protein, humanProto-Oncogene Proteins c-etsTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.